<DOC>
	<DOCNO>NCT02349347</DOCNO>
	<brief_summary>The purpose study assess efficacy intensify intravenous Melphalan combination transplant patient ' blood stem cell maximum three cycle . In recently complete small Phase I study look use high dos intravenous Melphalan combination lenograstim ( drug stimulate bone marrow produce white blood cell help fight infection ) patient ' blood infusion 4 cycle treatment prove encouraging . The result study show rapid improvement pain fall circulate tumour cell within two week start Melphalan . However , slow platelet recovery fourth cycle mean long period platelet transfusion . For trial intend ass efficacy intensify intravenous Melphalan transplant patient ' blood stem cell short time period . This study involve approximately 39 patient 3 year period .</brief_summary>
	<brief_title>A Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles Patients With Castration-resistant Prostate Cancer ( CRPC )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Men age ≥18 year Histological diagnosis prostate cancer Progressive Castrationresistant Prostate Cancer define : rise PSA ; development new site disease presence suppress testosterone ( &lt; 1.5 nmol/l ) ; testosterone &gt; 1.5 nmol/l , maximum androgen blockade failure ( MAB ) ( MAB = GnRH analogue peripheral antiandrogen flutamide 250 mg 3x/day bicalutamide 50 mg/ day cyproterone 100mg 3x/day ) ECOG performance status 02 Adequate haematological reserve : Unsupported Hb &gt; 9.0 g/l , Platelets &gt; 100x109/l , WBC &gt; 3x109/l , Neutrophils &gt; 1.5x109/l Renal sufficiency : Creatinine &lt; 200 µmol/l Hepatic sufficiency : Bilirubin &lt; 30 µmol/l , ALT &lt; 3xULN unless due liver metastasis Able give write informed consent comply protocol study procedures Patients suffer previous hypersensitivity reaction melphalan Patients know hypersensitivity lenograstim excipients History myeloid malignancy Lenograstim administer concurrently cytotoxic chemotherapy ( i.e . day ) Previous invasive carcinoma &lt; 3 year prior study entry Cardiac condition contraindicate large volume venesection ( i.e. , active angina cardiac failure ) Current treatment another investigational medicinal ( chemotherapeutic ) product participation another investigational therapeutic ( chemotherapy ) study , time treatment period 30 day precede study entry . Life expectancy &lt; 12 week Unwilling unable provide write informed consent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>